Cue Biopharma Q2 2026: $153.1M Net Loss, Cash at $17.4M, July Placement Adds $49.8M
CUE has more than doubled off its 52-week low of $4.971.
Summary
Cue Biopharma's Q2 2026 10-Q reveals a $153.1M net loss, $17.4M in cash, and a July private placement that raised $49.8M. The Ascendant license deal adds significant future milestone obligations and potential dilution.
Updates
· Dow Jones Newswires — Q2 loss per share was $24.14, with revenue more than doubling to $7.88 million.
Key Events · Earnings and Guidance · CUE
-
Q2 Net Loss of $153.1M
Net loss of $153.1 million for Q2 2026, driven by a $90 million non-cash loss on liability-classified warrants and $35.1 million in Ascendant license expenses.
-
Cash Position and Runway
Cash and cash equivalents of $17.4 million at June 30, 2026. A July private placement added $49.8 million in net proceeds, extending runway to at least twelve months.
-
Ascendant License Agreement
License for CUE-221 includes $15 million upfront, up to $676.5 million in milestones, and a Top-Up Obligation that could give Ascendant 7.5% ownership.
-
Private Placements
May 2026 offering raised $27.6 million; July 2026 offering raised $49.8 million at $33.21 per share.
Analysis · CUE · Life Sciences
A $153.1 million net loss for Q2 2026 stemmed from a $90 million non-cash loss on liability-classified warrants and $35.1 million in expenses tied to the Ascendant license deal. Cash fell to $17.4 million at quarter-end, but a $49.8 million private placement in July extends the runway to at least twelve months. The filing also details the Ascendant license terms, including up to $676.5 million in potential milestone payments and a Top-Up Obligation that could dilute shareholders by 7.5%.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 35.9% of the 1030 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CUE was trading at $33.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $143.7M. The 52-week trading range was $4.97 to $45.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.